New sedation drug may reduce breathing risks during heart procedure

NCT ID NCT07532733

Recruiting now Symptom relief Sponsor: Erasme University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two sedation approaches during a minimally invasive heart valve replacement (TAVI) in 80 elderly patients. One group receives dexmedetomidine, a sedative that may cause less breathing depression, while the other gets standard propofol-remifentanil. Researchers will monitor breathing problems like low oxygen or slow breathing during the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dexmedetomidine
What this could lead to: If dexmedetomidine proves safer, it could become the preferred sedation method for TAVI, reducing breathing complications in elderly patients.
What could go wrong: This is a small, early-phase study (80 participants) comparing two sedation drugs. Results may not apply to all patients or settings, and both drugs have known side effects like low heart rate or blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE AORTIC STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TAVI(TRANSCATHETER AORTIC VALVE IMPLANTATION)

Contacts and locations

Locations

HUB Erasme
RECRUITING

Brussels, 1070, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.